Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Rogers, Shaw and Quebecor Extend Outside Date of Proposed 17-02-2023, 19:11

New report from Meltwater and We. Communications reveals 90% of PR teams are integrating generative AI into their workflows 14-01-2026, 20:00